Vivozon stated Thursday that it has accomplished a patent registration in China for VVZ-2471, an oral, non-opioid analgesic in improvement. It’s the drug’s third abroad patent registration, following the US and South Africa.
VVZ-2471 is a brand new drug candidate developed with non-preserved multitarget drug discovery expertise, which has analgesic efficacy and drug dependancy remedy results. Vivozon is creating the drug as a remedy for neuropathic ache in Korea and as a remedy for drug dependancy within the U.S.
Vivozon obtained home approval from the Ministry of Meals and Drug Security final June for the part 2 medical trial IND of VVZ-2471 for postherpetic neuralgia sufferers. Outcomes are anticipated this yr. The corporate plans to make use of it to deal with ache, together with the thirty eighth homegrown new drug, Unafra Injection (opiranserine hydrochloride).
Within the U.S., it’s getting ready for part 2 to develop VVZ-2471 as a drug dependancy remedy. To this finish, the corporate has utilized for a grant from the U.S. Nationwide Institute on Drug Abuse (NIDA) and is collaborating with native consultants.
“There’s an absence of a non-narcotic analgesic with efficacy similar to narcotic analgesics within the painkiller market,” a Vivozon official stated. “We are going to develop VVZ-2471 as a non-narcotic acute and continual oral analgesic and lead the worldwide painkiller market with Unafra.”
